Vaccinations / Vaccination Subsidies

VACCINATION SUBSIDIES

With effect from 1st November 2020, the following vaccination subsidies will be made available to eligible patients at all our clinics according to the National Adult & Child Immunisation Schedule.

The following table shows what an eligible patient would pay in our clinics.

 
 

Expand sections to view eligibility criteria for a subsidised vaccination.


Combined 6-in-1, Combined 5-in-1, & Tdap (Child)


Recommended vaccine types and doses 

  • Dose 1: 6-in-1 vaccine at 2 months  

  • Dose 2: 5-in-1 vaccine at 4 months  

  • Dose 3: 6-in-1 vaccine at 6 months  

  • Dose 4: 5-in-1 vaccine at 18 months (booster 1)  

  • Dose 5: Tdap-IPV at 10-11 years (booster 2)  

Tdap can be used instead of Tdap-IPV if IPV is not indicated


Influenza


Child

  • Seasonal influenza vaccine is recommended for persons age 6 months to 17 years who are at increased risk of influenza-related complication. 

  • Vaccination is recommended annually or per season, depending on the prevailing recommendations for that year.  

  • Influvac Tetra and SKYCellflu are indicated from age 3 years. 

Recommended doses 

Age 6 months to 8 years  

  • 2-dose series 4 weeks apart for children receiving influenza vaccination for the first time  

  • 1 dose for all other children* 

Age 9-17 years  

  • 1 dose* 

* Annually or per season as recommended 

High-risk groups recommended for seasonal influenza vaccine 

Children age 6 months to <5 years (6-59 months)  

  • Recommended for all children in this age range 

Persons age 5-17 years  

  • who have chronic disorders of the pulmonary or cardiovascular systems, including asthma  

  • who have required medical follow-up or hospitalisation due to chronic metabolic diseases (including diabetes mellitus), renal, neurologic, hepatic, or haematologic disorders, or immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)  

  • who are receiving long term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection


Adult

  • Seasonal influenza vaccine is recommended for persons age 18 years or older who are at increased risk of influenza-related complications. 

  • Vaccination is recommended annually or per season, depending on the prevailing recommendations for vaccination that year.  


High-risk groups recommended for seasonal influenza vaccination 

Persons age 65 years or older  

  • Recommended for all persons age 65 years or older 

Persons age 18-64 years  

  • who have chronic disorders of the pulmonary or cardiovascular systems, including asthma  

  • who have required medical follow-up or hospitalisation due to chronic metabolic diseases (including diabetes mellitus), renal, neurologic, hepatic, or haematologic disorders, or immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies) 

Other recommended groups  

  • Persons age 18 years who are receiving long term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection  

  • Women at all stages of pregnancy  

  • Persons receiving intermediate and long term care (ILTC) services


MMR


Child

Recommended doses:
Dose 1: 12 months (to be taken separately from the varicella vaccination)
Dose 2: 15 months (can be taken with together with varicella, or as the combined MMRV/Priorix-Tetra vaccination)

Adult

MMR is recommended for persons without evidence of immunity or prior disease  

  • 2-dose series at least 4 weeks apart


Hepatitis B


Child

Recommended vaccine types and doses  

  • Dose 1: Monovalent HepB (birth dose, within 24 hours)  

  • Dose 2: 6-in-1 vaccine at 2 months  

  • Dose 3: 6-in-1 vaccine at 6 months 

Infants born to HBsAg +ve mothers  

  • Dose 1: Monovalent HepB (and HepB immunoglobulin (HBIG) as a birth dose within 12 hours or ASAP)  

  • Dose 2: Monovalent HepB at 1 month  (5-in-1 vaccine recommended at 2 months)  

  • Dose 3: 6-in-1 vaccine at 6 months

Adult

HepB is recommended for patients without evidence of immunity or prior disease (subsidies only apply to patient with serological evidence of non-reactive immune status).

  • 3-doses series at 0, 1, 6 months


Pneumoccocal (PCV13)


Child

PCV is recommended for all children age <5 years and persons age 2-17 years who are at increased risk of developing severe pneumococcal disease. Children who did not receive PCV as per routine schedule are recommended to receive age- or indication appropriate doses.  

High-risk groups recommended for PCV13 

Persons age 2-17 years with  

  • Cochlear implant or cerebrospinal fluid leak  

  • Anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction)  

  • Immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)

Adult

  • PCV13 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease.  

  • One dose is recommended regardless of age or indication.  

High-risk groups recommended for PCV13 

Persons age 65 years or older  

  • Recommended for all persons 

Persons age 18-64 years with  

  • cochlear implant or cerebrospinal fluid leak  

  • anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction) 

  • Immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)


Pneumococcal (PPSV23)


Child

  • PPSV23 is recommended for persons age 2-17 years at increased risk of developing severe pneumococcal disease.  

  • One or two doses are recommended depending on high-risk condition.  

High-risk groups recommended for PPSV23 

Persons age 2-17 years with  

  • Chronic pulmonary, cardiovascular, renal or liver disease, or diabetes mellitus  

  • Cochlear implant or cerebrospinal fluid leak  

  • Anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction)  

  • Immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)


Adult

  • PPSV23 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease.  

  • One or two doses are recommended depending on indication.  

High-risk groups recommended for PPSV23 

Persons age 65 years or older  

  • Recommended for all persons 

Persons age 18-64 years with  

  • chronic pulmonary, cardiovascular, renal or liver disease, or diabetes mellitus

  • cochlear implant or cerebrospinal fluid leak  

  • anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction)  

  • immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)


Tdap (Adult)

  • Tdap is recommended during 16-32 weeks of each pregnancy for protection of infant against pertussis, regardless of the interval since the previous Td or Tdap vaccination.  

  • Tdap is recommended with each pregnancy to provide maximal protection to every infant, including pregnancies which are closely spaced (e.g. <2 years).  

  • Tdap can also be considered for pregnant women after 32nd week of gestation during each pregnancy. Maternal vaccination may afford less protection for infants, but would potentially protect the mother from pertussis infection and thereby reduce the risk of exposure to her infant.  

  • The use of Adacel has not been evaluated in pregnant women.


Varicella (Chickenpox)


Varicella vaccination is recommended for persons without evidence of immunity or prior disease  

  • 2-dose series 4-8 weeks apart


For more information, please refer to the National Adult & Child Immunisation Schedule.